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Since emerging in Wuhan, China, in December 2019, severe 
acute respiratory syndrome coronavirus-2 (SARS-CoV-2, 
has led to more than 95 million confirmed cases of COVID-
19 and more than 2 million deaths worldwide (numbers 
accurate as of January 19, 2021).1 COVID-19 is a conta-
gious disease that generally causes mild symptoms that 
include fever, a dry cough, and tiredness. Approximately 
10%–15% of cases progress to severe disease, and about 
5% of those infected become critically ill.2 Currently, only 
supportive care is available. Multiple COVID-19 variants 
are circulating globally (including variants in the UK, South 
Africa, and Brazil) that appear to spread more easily and 
quickly than other variants. Currently, there is no evidence 
that these variants cause more severe illness or increased 
risk of death. However, this has increased the burden placed 
on healthcare systems around the world, and there is a 
pressing need for the discovery and development of thera-
peutic agents to treat this disease. The quickest way to 
achieve this is to repurpose approved drugs developed for 
other uses, and thereby take advantage of existing informa-
tion on human pharmacology and toxicology to enable 
rapid clinical trials.
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Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) represents a significant threat to human health. Despite 
its similarity to related coronaviruses, there are currently no specific treatments for COVID-19 infection, and therefore 
there is an urgent need to develop therapies for this and future coronavirus outbreaks. Formation of the cap at the 5′ end 
of viral RNA has been shown to help coronaviruses evade host defenses. Nonstructural protein 14 (nsp14) is responsible 
for N7-methylation of the cap guanosine in coronaviruses. This enzyme is highly conserved among coronaviruses and 
is a bifunctional protein with both N7-methyltransferase and 3′-5′ exonuclease activities that distinguish nsp14 from its 
human equivalent. Mutational analysis of SARS-CoV nsp14 highlighted its role in viral replication and translation efficiency 
of the viral genome. In this paper, we describe the characterization and development of a high-throughput assay for nsp14 
utilizing RapidFire technology. The assay has been used to screen a library of 1771 Food and Drug Administration (FDA)-
approved drugs. From this, we have validated nitazoxanide as a selective inhibitor of the methyltransferase activity of 
nsp14. Although modestly active, this compound could serve as a starting point for further optimization.
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SARS-CoV-2 is a positive-sense single-stranded RNA 
virus belonging to the beta genus of the Coronaviridae family.3 
Like all viruses, SARS-CoV-2 is fully reliant on the transla-
tion machinery of its host cells to translate RNA into the pro-
teins that are essential for its survival. In order to protect itself 
from cellular innate immunity, viral mRNA of SARS-CoV-2 
possesses a cap structure at the 5′-end of the polynucleotide, 
consisting of an N-methylated guanosine triphosphate and a 
C2′-O-methyl-ribosyladenine.4 Similar cap structures exist 
on eukaryotic cellular mRNAs;5 however, the cap is 
installed on RNA during transcription in the nucleus, and 
therefore coronaviruses, such as SARS-CoV-2, do not have 
access to the mammalian capping enzymes. Instead, coro-
naviruses encode their own cap-synthesizing enzymes.6 
Four nonstructural proteins (nsp) are thought to be involved 
in the capping process: nsp10, nsp13, nsp14, and nsp16. 
The primary function of nsp13 is the unwinding of viral 
RNA during replication,7 but it also has 5′-RNA triphospha-
tase activity;8 thereby it is responsible for cleaving mono-
phosphate at the 5′-end of the polynucleotide. The protein 
responsible for initial cap creation, the guanylyltransferase, 
is not known. Nsp14 and nsp16 are responsible for the 
methylation of the cap on the guanine of the GTP and the 
C2′-hydroxyl group of the following nucleotide, respec-
tively.9–13 Both are S-adenosylmethionine (SAM)-dependent 
methyltransferases (MTases). Nsp10 is known to interact 
with nsp14 and nsp16 and regulate their respective ExoN 
and 2′-O-MTase activities.12,14 Nsp10 is an allosteric regu-
lator that stabilizes nsp16.11 In addition, nsp16 binding 
extends and narrows the RNA-binding groove that accom-
modates the RNA substrate, thereby promoting the RNA- 
and SAM-binding capabilities of nsp16.
Nsp14 is well conserved within the Coronaviridae fam-
ily.15 It is a bifunctional protein with both N7-MTase and 
3′- to 5′-exonuclease (ExoN) activities. While the associa-
tion of nsp10 with nsp14 stimulates the ExoN activity of 
nsp14 by >35-fold,16 there is no evidence that it has any 
effect on N7-MTase activity. The specific role of N7-MTase 
activity in virus replication is supported by reverse genetics. 
Chen et al. have introduced point mutations into a SARS-
CoV-1 replicon carrying a luciferase reporter.9 A D331A 
mutation (MTase domain) led to reduction of luciferase 
activity by 90% and the copy number of subgenomic RNA 
by 81%. More recently, mutations in murine hepatitis virus 
nsp14 at G332 within the MTase domain resulted in delayed 
replication kinetics and decreased peak titers relative to 
wild-type.17 In addition, replication of nsp14 G332A virus 
was diminished following treatment of cells with IFN-β, 
and nsp14 G332A genomes were translated less efficiently 
both in vitro and during viral infection. Taken together, 
these results demonstrate that the N7-MTase activity of 
nsp14 plays an important role in viral replication.
Nsp14 N7-MTase is an attractive target for antiviral strate-
gies. Although its overall structure is similar to the human 
homolog, RNA guanine-N7-methyltransferase (RNMT), 
there is very little sequence conservation in the active site 
(7% sequence identity between RNMT and SARS-CoV-2 
nsp14 was calculated using SuperPose;18 RNMT (PDB:5E8J) 
and a SARS-CoV-2 homology model based on the SARS-
CoV-1 nsp14 structure (PDB:5C8U) were used for this com-
parison), suggesting that molecules with selectivity for the 
viral protein should be achievable. The ligandability of the 
enzyme with small molecules has been demonstrated with 
known MTase inhibitors. In vitro assays revealed that 
S-adenosyl-l-homocysteine (the by-product of the methyla-
tion reaction), sinefungin, and aurintricarboxylic acid (ATA) 
efficiently inhibit nsp14 N7-MTase activity with IC50 values 
of 16 µM, 496 nM, and 6.4 µM, respectively.19 ATA was also 
shown to limit SAR-CoV replication in infected cells.20 
Taken together, nsp14 represents a novel, viable drug target 
for the treatment of COVID-19 and potentially more widely 
across the Coronaviridae family. Herein, we report the devel-
opment of a mass spectrometry (MS)-based high-throughput 
screen in order to identify small-molecule inhibitors of the 
N7-MTase activity of SARS-CoV-2 nsp14. Using this tech-
nology, we screened a library composed of 1771 Food and 
Drug Administration (FDA)-approved small molecules.
Materials and Methods
All aqueous solutions were prepared with deionized water 
(Millipore, Watford, Hertfordshire, UK). All reagents 
were purchased from Sigma Aldrich (Gillingham, Dorset, 
UK) unless otherwise stated. Full-length SARS-CoV-2 
nsp14 protein (DU66418) was supplied by the MRC-PPU 
(Dundee, UK). Nsp14 was cloned in fusion with a cleavable 
N-terminal GST fusion in a pGEX6P1 vector and expressed 
in Escherichia coli. Nsp14 was purified by batch purifica-
tion using GSH-Sepharose beads and the tag was cleaved 
by PreScission protease. Cleaved nsp14 was delivered in 50 
mM Tris, pH 7.5, 150 mM NaCl, 270 mM sucrose, 0.1 mM 
EGTA, 0.03% Brij-35, 0.1% β-mercaptoethanol at 1.23 mg/
mL. Full-length human RNMT:RAM (1–90) was coex-
pressed using conditions developed internally.
Description of the Screening Library
The DiscoveryProbe FDA-approved drug library (https://
www.apexbt.com) is a unique collection of 1771 small-
molecule, FDA-approved drugs with known bioavailability 
and safety data in humans.
Nsp14 RapidFire MS High-Throughput 
Screening Assay
An endpoint 384-well plate assay was developed to assess 
nsp14 activity. Briefly, enzyme and substrates, SAM (S-(5′-
adenosyl)-l-methionine chloride hydrochloride [Cayman 
Chemical, Ann Arbor, MI] and cap G(5′)ppp(5′)G sodium 
salt [New England Biolabs, Ipswich, MA]) were incubated to 
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allow the reaction to take place, and then the product was 
quantified using MS. Assays were performed in 384-well, 
clear, flat-bottom plates (Greiner 781101) to a final volume 
of 20 µL. Components were diluted in buffer (20 mM Tris, 
pH 8.0, 50 mM NaCl) containing 1 mM TCEP (Thermo 
Scientific, Waltham, MA), 0.1 mg/mL bovine serum albu-
min, 0.005% Nonidet P40 (Roche), and 3 mM MgCl2. In the 
assay, 5 nM nsp14 was incubated with 1 µM SAM and 0.7 
µM cap (FAC). Following a 60 min incubation, the reaction 
was quenched using 1% formic acid (VWR, Radnor, PA) 
containing 0.03 µg/mL S-adenosylhomocysteine-d4 (d4SAH; 
Cambridge Bioscience, Cambridge, UK) and loaded on the 
RapidFire system by aspiration for 600 ms using the Agilent 
RapidFire 365 high-throughput system with integrated solid-
phase extraction (SPE) interfaced with the Agilent 6740 tri-
ple quadrupole mass spectrometer. The sample was then 
automatically loaded onto a C18 Type C SPE cartridge 
(Agilent Technologies), and buffer salts and protein matrix 
were removed from the sample by washing the cartridge with 
the load solution (water containing 0.1% trifluoroacetic acid 
[TFA]) at a flow rate of 1.5 mL/min for 5000 ms. The retained 
and purified analytes were eluted from the cartridge with the 
elution solution (acetonitrile: water [9:1, v/v] containing 
0.1% TFA) at 1.25 mL/min for 5000 ms and directed to the 
mass spectrometer. The cartridge was reequilibrated with 
load solution at 1.5 mL/min for 500 ms.
Both S-adenosylhomocysteine (SAH) and d4SAH were 
assessed using multiple selected reaction monitoring 
(MRM) transitions of 385.1/134 for SAH and 389.2/135.9 
for d4SAH. The dwell time was 50 ms for each transition. 
The fragmentor voltage was set to 120 V for SAH and 100 
for d4SAH, the collision energy to 12 V for SAH and 14 V 
for d4SAH, the cell accelerator voltage to 5 V, and the delta 
electron multiplier voltage to 200 V. The mass spectrometer 
was operated with a gas temperature of 350 °C, gas flow 
rate of 7 L/min, nebulizer pressure of 40 psi, and capillary 
voltage of 3000 V. The areas under the daughter ion peaks 
of SAH and d4SAH were integrated using RapidFire QQQ 
Quantitative Analysis software (Agilent Technologies), and 
the area ratios of the SAH to the internal standard d4SAH 
were used for quantitation. A representative chromatograph 
showing a time course of nsp14 in this assay has been 
included in the supplemental files (Suppl. Fig. S1).
SAM Enzyme Kinetics
To determine the kinetics for SAM, a twofold serial dilution 
was performed from a top concentration of 20 µM, with 20 
µM cap. Reaction was initiated by addition of 10 nM nsp14 at 
multiple time points, and the plate was read using RapidFire. 
Data collected from the experiment were analyzed to calcu-
late initial velocities and obtain KM values using the Michaelis–
Menten equation (SigmaPlot version 14.0; Systat Software, 
Inc., San Jose, CA). KM
app values are presented as the mean of 
three independent experiments with the 95% CI.
Cap Enzyme Kinetics
To determine the kinetics for cap, a twofold serial dilution 
was performed from a top concentration of 20 µM, with 
20 µM SAM. Reaction was initiated by addition of 10 nM 
nsp14 at multiple time points, and the plate was read using 
RapidFire. Data were analyzed as described previously.
Assay Development
An optimal nsp14 concentration was established using a 
range of concentrations starting from 15 nM, with incuba-
tion times up to 120 min to establish the most appropriate 
incubation time when using established screening concen-
trations of substrates. Assay DMSO (VWR) tolerance was 
tested from 5%, added using the Preddator Reagent 
Dispenser (Redd and Whyte, London, UK) with a single 
incubation time of 60 min. The impact of addition of nsp10 
on apparent nsp14 activity was assessed by titrating nsp10 
into the assay from a top concentration of 20 nM, using pre-
viously established screening concentrations of substrates 
and nsp14, with incubation times up to 60 min. Reagent 
stability experiments were carried out whereby reactions 
were started 0, 1, 2, and 4 h after reagent preparation, with 
and without the addition of nsp10 at equimolar concentra-
tions to nsp14. All reagents were maintained at room tem-
perature throughout the course of the experiment, and the 
assay was run for a single incubation time of 60 min. Assay 
robustness was assessed by performing a mock screen, con-
sisting of two empty 384-well plates, one of which con-
tained compounds from our assay interference set. Assay 
performance was further assessed by screening the SAM 
mimetic, sinefungin, at a 10-point, 1:2 serial dilution from 
100 µM. For calibration curves, SAH was spiked into the 
assay at concentrations from 0.017 to 10 µM in assay buffer 
and quenching solution containing 0.08 µM internal stan-
dard (d4 SAH) and measured by RapidFire MS/MS (Suppl. 
Fig. S2).
Compound Testing
For compound testing, DMSO stocks of the FDA library 
compounds and DMSO backfill were dispensed (0.02 μL of 
constant total volume, 0.1% of the final assay volume for 
single-point testing, 0.2 µL of constant total volume, 1% of 
the final assay volume for 10-point dose–response testing) 
into dry 384-well assay plates (Greiner 781101) using the 
Echo 550 acoustic dispenser (Labcyte, Sunnyvale, CA), 
giving a final assay concentration of 10 µM. The enzyme 
solution (10 μL) was added to predispensed compounds 
first, and then addition of the substrate solution (10 μL) ini-
tiated the reaction. The inhibitory activity was calculated 
using the peak area ratio, which is the reaction product 
(SAH) divided by its internal standard (d4SAH). We defined 
the peak area ratio of the reaction without enzyme as 100% 
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inhibitory activity and that of the complete reaction mixture 
as 0% inhibitory activity.
Curve fitting and calculations of IC50 values were under-
taken using ActivityBase XE version 9.2.0.106 from IDBS. 
A four-parameter logistics dose–response curve (model 
203) was utilized with prefit for all four parameters. Unless 
otherwise stated, all IC50 values are presented with 95% 
confidence intervals with the associated n values.
In Vitro Cap Guanosine N7-Methyltransferase 
Assay
Cap MTase assays were performed according to Cowling, 
with minor alterations.21 In brief, 33 nM recombinant SARS-
CoV-2 nsp14 was incubated with a stated concentration of 
nitazoxanide for 10 min at 18 °C. An in vitro transcribed 55 
nt 32P-capped RNA substrate (sequence 5′-G GGCGA 
ATTGG GCCCG ACGTC GCATG CTCCC GGCCG 
CCATG GCGGC CGCGG GAAT-3′) and 100 nM SAM 
were added and the mixture was maintained at 30 °C for 15 
min. RNA was purified using phenol–chloroform and pre-
cipitated with sodium acetate. RNA was digested with P1 
nuclease and cap structures were resolved on PEI cellulose 
in 0.4 M ammonium sulfate. The migration of caps was 




The nsp14 enzyme concentration range that linearly corre-
lated with the initial velocity was determined using 20 µM 
(saturating) cap and SAM. A linear relationship with initial 
velocity was established up to 30 min for all enzyme con-
centrations screened (2.5–20 nM) (Fig. 1A and Suppl. Fig. 
S3). A concentration of 10 nM for nsp14 was selected for 
characterization of cap and SAM kinetics due to this con-
centration being relatively low but giving a signal window 
that is sufficient for observing enzymatic activity. Assuming 
all of the protein is active, the kcat is calculated to be 0.088 
per second. The KM
app values of the substrates cap and SAM 
were determined as 0.23 µM (0.15–0.35 µM; n = 3) and 
0.69 µM (0.51–0.92 µM; n = 3), respectively (Fig. 1B,C). 
Typically, substrate concentrations would be screened at 
close to KM, as this provides assay conditions suitable for 
identifying the widest range of inhibitor modalities. Hence, 
concentrations of 0.7 µM cap and 1.0 µM SAM were 
selected for use in the assay as being close to KM and giving 
a robust signal (signal-to-background ratio > 5 and Z′ > 
0.6) suitable for screening (where Z′ = 1 – ((3 × σhigh signal 
+ 3 × σlow signal)/(µhigh signal – µlow signal))).
In order to establish screening conditions for nsp14 
under the KM conditions above, 5 and 10 nM nsp14 were 
tested at a range of time points, with 5 nM nsp14 being lin-
ear up to 90 min (Fig. 1D). Therefore, a 60 min incubation 
time and 5 nM nsp14 were selected for use in our screen as 
we were within the linear range of the assay and had a signal-
to-background greater than 5, with a Z′ greater than 0.6.
As our screening compounds are solubilized in DMSO, 
the tolerance of the enzyme assay to this solvent was 
assessed. Industry standard assays require a tolerance of at 
least 0.5% DMSO.22 Using the established enzymatic con-
ditions, DMSO tolerance was evaluated up to 5% DMSO. 
Our assay was found to be tolerant up to approximately 2% 
DMSO (Suppl. Fig. S4). At 5% DMSO, the nsp14 retained 
70% activity relative to 0% DMSO control.
Nsp14 MTase activity is reported to be independent of 
nsp10.23 In order to confirm this, we performed a titration of 
nsp10 (0–20 nM) using the established assay conditions 
described above. We found that neither increasing concen-
trations of nsp10 (Suppl. Fig. S5) nor extended preincuba-
tion of nsp10 with nsp14 (Fig. 1E) had any effect on the 
assay.
Assay Robustness
To assess assay robustness and the signal-to-noise ratio, a 
mock screen without inhibitors was performed. Two 384-
well plates were used, and the last column in both cases 
lacked the enzyme. The robustness Z′ values were 0.66 and 
0.63, and the signal-to-background ratios were 9.1 and 8.4, 
respectively. In addition, the overall plate coefficients of 
variation for wells containing nsp14 and substrates were 
7.8% and 8.0%. These values are acceptable for high-
throughput screening.
Additionally, to evaluate what type of undesirable 
screening compounds our assay was susceptible to picking 
up as false positives, we screened our interference set, 
which consists of 24 compounds with known liabilities: 
redox cyclers, aggregators, metal chelators and other com-
pounds that are known to interfere with a variety of assay 
technologies (see Suppl. Fig. S6A). The set was screened at 
10 µM under the assay conditions identified above. Only 
one compound, N-(3-fluorophenyl)maleimide, resulted in a 
percentage effect greater than 50% (Suppl. Fig. S6B); vari-
ous other covalent inhibitors did not produce a statistically 
significant effect. As the compound screening collections 
that we planned to use in our high-throughput screen are 
devoid of covalent inhibitors, we were not concerned with 
this result.
Assay Validation
In order to validate the nsp14 MS-based assay we have 
developed, we performed a dose–response study with a 
known MTase inhibitor, sinefungin (Fig. 1F). Sinefungin 
inhibited nsp14 with an IC50 of 0.2 µM (0.1–0.3 µM; n = 4).
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Figure 1. Enzyme kinetics and assay development. Standard curves were used to determine the concentration of SAH produced by 
reaction. (A) Reaction time course up to 90 min to determine initial rates. Nsp14 was tested at 20, 10, 5, and 2.5 nM; 20 µM was the 
concentration for both SAM and cap. (B) Determination of apparent KM (KM
app) for cap with nsp14. Nsp14 was tested at 10 nM; the 
cap was titrated from 20 to 0 µM for 60 min. The results are representative of three independent experiments. (C) Determination 
of apparent KM (KM
app) for SAM with nsp14. Nsp14 was tested at 10 nM; SAM was titrated from 20 to 0 µM for 60 min. The results 
are representative of three independent experiments. (D) Determination of the incubation time range and nsp14 concentration using 
KM
app for both cap and SAM. Nsp14 was tested at 10 and 5 nM. (E) Comparison of reagent stability following preincubation at a range 
of time points prior to the assay, with or without the addition of nsp10. The impact on assay stability was determined by comparison 
of Z′. (F) Dose–response testing of sinefungin against nsp14 using established screening conditions. Compound was tested at 10 
concentrations, 1:2 from 100 µM (top concentration). Data are shown as mean ± SD. The IC50 value was 0.2 µM (0.1–0.3 µM; n = 4).
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Primary Screen
Having optimized assay conditions, we proceeded to screen 
the 1771 compounds in the DiscoveryProbe FDA-approved 
drug library against SARS-CoV-2 nsp14 at a single concen-
tration of 10 µM. The assay performed robustly, with an 
average Z′ of 0.78 (± 0.02) and an average signal-to-back-
ground ratio of 10.45 (the signal-to-background ratio varied 
between 9.7 and 10.94). The mean percent effect detected 
was 0.57 with an SD of 8.57. The screen identified 12 hits 
(hit rate of 0.7%), with hits defined as compounds produc-
ing >26% effect on nsp14 activity (mean + 3 SD). All but 
one of these putative hits were progressed to a full dose 
response, with nine showing a half maximal inhibitory con-
centration (IC50) of <100 µM (Suppl. Table 1).
 Included in 
this set were the natural flavonols kaempferol and 
3′-hydroxykaempferol, which produced IC50 values of 28 
µM (25.1–31.6 µM; n = 2) and 20 µM (15.8–25.1 µM; 
n = 2), respectively. These compounds have previously 
been shown to inhibit SARS-CoV-1 nsp14.21 The most 
potent compound was nitazoxanide (1) (Fig. 2A), which 
had an IC50 against SARS-CoV-2 nsp14 of 9.7 µM (6.3–
15.1 µM; n = 4) (Fig. 2B) and a maximal effect of 89.7%. 
This compound is of interest as it is already being explored 
as a potential therapy for COVID-19. In order to determine 
whether this compound specifically targets the viral RNA 
cap MTase of SARS-CoV-2, we screened it against the 
human homolog RNA RNMT, under similar conditions to 
those described above. Nitazoxanide showed no activity 
within the concentration range screened (IC50 > 100 µM).
Following oral administration, nitazoxanide is rapidly 
hydrolyzed to the pharmacologically active metabolite, 
tizoxanide (2) (Fig. 2A),24 which has not yet been studied 
for anti-SARS-CoV-2 activity. We therefore profiled 
tizoxanide under the assay conditions described above. 
Tizoxanide produced an IC50 against SARS-CoV-2 nsp14 of 
54.8 µM (27.3–110.0 µM; n = 4) and a maximal effect of 
62.0%.
Orthogonal Screen
In order to validate the nitazoxanide inhibition of nsp14 
observed in our high-throughput MS assay, we screened 
nitazoxanide in an MTase activity assay that utilizes guano-
sine-capped RNA as a substrate. In this assay, a titration of 
nitazoxanide was incubated with nsp14 prior to the addition 
of the 32P-guanosine-capped substrate and SAM. Following 
the methylation reaction, RNA was purified and digested by 
P1 nuclease to release cap structures, which were resolved 
by thin-layer chromatography. Forty-nine percent inhibition 
of N7-guanosine cap methylation was observed at 100 µM 
(Fig. 2C). Based on a titration of nitazoxanide (0.01–100 
Figure 2. Chemical 
structure and dose 
response of nitazoxanide 
against nsp14. (A) Chemical 
structures of nitazoxanide 
(1) and tizoxanide (2).  
(B) Dose–response 
testing of nitazoxanide and 
tizoxanide against nsp14 
in a primary screening 
assay. Compounds were 
tested at 10 concentrations, 
1:2 from 100 µM (top 
concentration). The IC50 of 
nitazoxanide was 9.7 µM 
(6.3-15.1 µM; n = 4), and 
the IC50 of tizoxanide was 
54.8 µM (27.3–110.0 µM;  
n = 4). (C) Dose–response 
testing of nitazoxanide 
against nsp14 in an 
orthogonal radiometric 
assay with a representative 
phosphoimage. Data are 
shown as mean ± SD.
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µM) under the assay conditions described above, we project 
an IC50 of 132 µM.
Discussion
The identification of inhibitors of SARS-CoV-2 is of sig-
nificant global interest at present. We, like others, believe 
that the quickest way to identify small-molecule inhibitors 
of this deadly virus, and address the current global health 
emergency, is to repurpose approved drugs developed for 
other uses. This approach allows the global community to 
take advantage of existing information on human pharma-
cology and toxicology, enabling rapid clinical trials.
Herein, we have reported the development of a screening 
platform to identify small-molecule inhibitors of the 
N7-MTase activity of nsp14, a key enzyme involved in gen-
erating RNA cap structures and essential in masking viral 
RNA from the host immune system. Our high-throughput 
MS-based assay allows direct, rapid, and label-free measure-
ment of SAH, the by-product from the nsp14-mediated trans-
fer of a methyl group from S-adenosyl-l-methionine (SAM). 
Compared with traditional fluorescence assays, MS-based 
assays are more sensitive and require less enzyme (reducing 
cost and the tight binding limit), have higher a signal-to-noise 
ratio, and produce more robust Z′. In addition, the direct 
detection of reaction product significantly minimizes the risk 
of identifying false-positive hits. Using this technology, we 
screened ApexBio’s DiscoveryProbe screening library, a 
chemically diverse set of 1771 FDA-approved small-mole-
cule drugs, at a single concentration of 10 µM. Under our 
optimized conditions, our assay performed robustly, with an 
average Z′ of 0.78 (± 0.02) and an average signal-to-back-
ground of 10.45. The hit rate was 0.7%, and we identified 12 
statistically significant hits, the most interesting of which was 
nitazoxanide. Nitazoxanide produced an IC50 against SARS-
CoV-2 nsp14 of 9.7 µM with a maximal effect of 92.1% and 
was selective for viral enzyme over the human homolog, 
RNMT (IC50 > 100 µM). Activity was confirmed in a cap 
MTase activity assay that directly measures methyltransfer to 
a 55 nt transcript. The 10-fold shift in activity observed 
between this assay and our primary biochemical assay could 
be the result of different assay conditions. It has, however, 
been observed that compounds that bind to the RNA-binding 
site of the enzyme show diminished activity when longer 
RNA substrates are used.25 Mode of inhibition studies would 
be useful to confirm whether nitazoxanide is indeed a cap 
competitive inhibitor.
Nitazoxanide is a commercial anti-infective agent with effi-
cacy in parasitic, bacterial, and viral infections. Nitazoxanide 
has antiviral activity against a range of human and animal 
coronaviruses, including Middle East respiratory syndrome 
coronavirus (MERS-CoV),26 and has recently been shown 
to be able to block SARS-CoV-2 in vitro infections at low 
micromolar concentrations (EC50 = 2.12 µM).
27 With 
MERS-CoV, nitazoxanide acts by blocking maturation of 
the viral nucleocapsid N protein that promotes production 
of the viral particles. Nitazoxanide is relatively safe in 
humans, and studies showed tolerability of single doses up 
to 4 g with minimal gastrointestinal side effects. This drug 
is currently being tested in a clinical trial (NCT04341493) 
as a stand-alone therapy (500 mg BID) and in combination 
with hydroxychloroquine for the treatment of COVID-19.
It is unlikely that the inhibition of viral replication 
seen in the cell-based assays described above is solely 
driven by the N7-MTase activity of nitazoxanide. These 
results have, however, identified a validated and selective 
chemical inhibitor of this important viral target, and this 
compound could serve as a starting point for further 
optimization.
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